Filed by Bristol-Myers Squibb Companyd18rn0p25nwr6d.cloudfront.net/CIK-0000014272/9909e384-c...Filed...
38
Filed by Bristol-Myers Squibb Company Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Form S-4 File No.: 333-229464 Subject Company: Celgene Corporation SEC File No.: 001-34912 Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at an investor presentation on February 20, 2019.
Transcript of Filed by Bristol-Myers Squibb Companyd18rn0p25nwr6d.cloudfront.net/CIK-0000014272/9909e384-c...Filed...
Filed by Bristol-Myers Squibb CompanyPursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12of the Securities Exchange Act of 1934
Form S-4 File No.: 333-229464Subject Company: Celgene Corporation
SEC File No.: 001-34912Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at an investor presentation on February 20, 2019.